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Available online 8 March 2016Intestinal strongyles (IS) are the most important parasites of equids, due to their high preva-
lence worldwide, pathogenicity and the spread of drug-resistant populations. Despite the
large number of horses bred in Sardinia Island, Italy, no data are available on the efﬁcacy of an-
thelmintic compounds in the control of horse strongylosis. Therefore the aim of the present
study was to evaluate the efﬁcacy of ﬁve commercial anthelmintic formulations containing
fenbendazole (FBZ), pyrantel (PYR), moxidectin (MOX) and two ivermectin formulations
(IVM1 and IVM2) against IS in Sardinia by performing a fecal egg count reduction test
(FECRT) and investigating the egg reappearance period (ERP) after treatment. In total, 74 horses
from 7 farms were examined. Coprocultures performed for individual fecal samples collected at
the day of the treatment revealed that cyathostomins were the predominant parasitic species
(98.6%). The FECR for all horses belonging to the treatment groups after two weeks was ≥95%
with a 95% C.I. N90%. The expected ERP did not decrease in any of the treatment group as FECR
values b90% were found at D60 for FBZ, at D90 for PYR and IVM1, at D150 for IVM2. All horses
treated with MOX showed FECRT N90% for the entire duration of the trial until D150. The results
of the present survey indicate that drug-resistant cyathostomin populations are not present in the
examined horse population, contrariwise towhat observed in other Italian and European regions.
The reasons and implications of these results are discussed.
© 2016 TheAuthors. Published by Elsevier Ltd on behalf ofWorld Federation of Parasitologists. This






The most common and pathogenic parasitic nematodes of horses are members of the family Strongylidae, which includes large
(Strongylinae Subfamily) and small (Cyathostominae Subfamily) strongyles. Intestinal strongyles (IS) of horses have a primary
importance in equine medicine, for their worldwide distribution and impact on health and performance of infected animals
(Heidi and Wade, 2009). In particular, small strongyles, also known as cyathostomins, are regarded as the most important
helminth parasites of horses for their cosmopolitan diffusion and their pathogenic potential at both larval and adult stages
(Peregrine et al., 2014). Currently, the control of IS infections is based on the use of systematic anthelmintic treatments and,
when applied, on management measures, e.g. removal of feces from paddocks and grazing rotation (von Samson-Himmelstjerna,
2012;Nielsen et al., 2014; Papini et al., 2015). The abuse of anthelmintic for a long time in the so-called “blanket treatments” approachri, Italy.
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16 G. Sanna et al. / Parasite Epidemiology and Control 1 (2016) 15–19has caused a worldwide distribution of anthelmintic resistance (AR) in cyathostomin populations (Heidi and Wade, 2009; von
Samson-Himmelstjerna, 2012; Nielsen et al., 2014). In particular, resistance to BZ such as fenbendazole (FBZ) is common and wide-
spread, and increasingly reported for tetrahydropyrimidines, such as pyrantel salts (PYR). Macrocyclic lactones (MLs), i.e. ivermectin
(IVM) and moxidectin (MOX), are still the most effective compounds against cyathostomins, despite reduced efﬁcacy has been re-
ported in both Europe and the Americas, especially for IVM (Traversa et al., 2009; Lyons et al., 2011; Molento et al., 2012; Traversa
et al., 2012). In Italy, cyathostomins are widespread in horse populations, with prevalence up to 100% (Traldi et al., 1988; Piergili-
Fioretti et al., 2005; Pilo et al., 2012); resistance to BZ, PYR and IVM has been reported in Italy (Traversa et al., 2009; Genchi et al.,
1992; Traversa et al., 2007), with reduction of the Egg Reappearance Period (ERP) of IVM and MOX in few premises (Geurden
et al., 2014). The evaluation of the ERP is crucial in understanding a possible onset of reduced efﬁcacy in these parasiticides, especially
for macrocyclic lactones (Sangster, 1999). It is worthy of note that the treatment efﬁcacy in most studies is evaluated through a fecal
egg count reduction test (FECRT) at up to 21 days after treatment. This approachmight underestimate a potential reduction in
anthelmintic efﬁcacy of MLs, as reduced activity of IVM and MOX is initially apparent from a shortened ERP after treatment,
and not necessarily from a reduced efﬁcacy within few weeks after treatment (Lyons et al., 2011).
Despite the large number of horses bred in Sardinia island of Italy (17,066 heads, representing 4.3% of the national heritage
395,913), no reliable data are available on the efﬁcacy of anthelmintics in this area (Montinaro et al., 2002). Therefore, the present
study aimed at updating current knowledge on the efﬁcacy and ERP of ﬁve commercial anthelmintic formulations commonly used
for the control of IS in horses bred in Sardinia.2. Materials and methods
A total of 74 horses, 40 females and 34 males ranging from 6 months to 6 years old from 7 premises in Sardinia were exam-
ined in 2010 for the presence of IS infection. All the tested animals were born and bred in Sardinia.
No anthelmintic treatments were performed in selected animals in the three months before the trial. In these farms breeders
usually performed anthelmintic treatments once a year in the horses kept grazing and in paddock, while every 6 months in those
animals living in boxes. All horses enrolled in the trial were kept under the same original farming conditions until the end of the
study. Five different anthelmintics (oral paste/gel) licensed in Italy were evaluated; these were the most used in breedings in Sar-
dinia: FBZ [Panacur® pasta, MSD], PYR [Strike®, os pasta Acme], two containing ivermectin (IVM1) [Eqvalan® os pasta Merial],
(IVM2) [Eraquell® os pasta Virbac] and MOX [Equest® os gel Zoetis]. Animals were selected and randomly enrolled in one of
the ﬁve treatment groups according to the number of horses present in each farm as shown in Table 1. Treatment was adminis-
tered per os on Day (D) 0 after the estimation of the weight of each horse using a girth tape (Pavo and Virbac Horse Weight
Tape®). All horses were observed for at least one hour after treatment to ensure complete swallowing of the drug and to record
any side effects (e.g., sweating, mydriasis, colics). All the treatments were administered by the same person and laboratory per-
sonnel did not know to which group the sample belonged. The individual FECs of each horse was determined at day-7 prior to the
FECRT, and then weekly in the ﬁrst month after treatment (i.e., D7, D14, D21, D28), and thereafter, biweekly for the following
4 months (i.e., D45, D60, D75, D90, D105, D120, D135, D150) using McMaster slides according to Raynaud (Raynaud, 1970).
The FECRT was carried out according to the recommendations of the World Association for the Advancement of Veterinary Par-
asitology (WAAVP) for detection of anthelmintic resistance in horses (Coles et al., 1992). Percentage reductions in the fecal egg
count were determined for each treatment group with the following formula: 100 × (1 − post-treatment EPG arithmetic
mean/pre-treatment EPG arithmetic mean).
The cut-off limits for establishing appropriate efﬁcacy were arithmetic means FECR of 95% for MLs and N90% for FBZ and PYR
(Kaplan and Nielsen, 2010) and a 95% conﬁdence interval (CI) of efﬁcacy was calculated. The results of the FECRs were interpreted
for all the compounds as follows: (1) resistance present if FECR b90% for FBZ and PYR, ≥95% for MLs and the lower 95%
conﬁdence limit (LCL) b90%, (2) resistance suspected if FECR ≥90% for FBZ and PYR, ≥95% for MLs and/or LCL b90% and (3) no
resistance if FECR ≥90% for FBZ and PYR, ≥95% for MLs and LCL N90%.
The evaluation of the egg reappearance period (ERP) was also assessed, being deﬁned as the time between treatment and the
ﬁrst breaching of a 90% efﬁcacy threshold (Geurden et al., 2014) and based on the group arithmetic mean FEC. The standard
minimum ERP used were 42 days for PYR, 42–56 days for FBZ, 56–70 days for IVM and N91 days for MOX (Stratford et al., 2011).
Coprocultures were performed at D0 for each fecal sample and up to D150 in horses with EPG ≥ 150, in order to allow the
in vitro growth of third stage strongyle larvae (L3) (Roberts and O'Sullivan, 1950), that were thereafter identiﬁed using the
morphological keys by MAFF (MAFF (Ministry of Agriculture Fisheries and Food), 1986).Table 1
Anthelmintics evaluated for efﬁcacy against horse strongyles in a population of horses from Sardinia Island, Italy.
Group Horses enrolled Commercial name Company Molecule Administration Dose
IVM1 15 Eqvalan® Merial Ivermectin Oral 0.2 mg/kg BW
IVM2 17 Eraquell® Virbac Ivermectin Oral 0.2 mg/kg BW
MOX 10 Equest® Zoetis Moxidectin Oral 0.4 mg/kg BW
PYR 19 Strike® Acme Pyrantel pamoate Oral 6.6 mg/kg BW
FBZ 13 Panacur® MSD Fenbendazole Oral 7.5 mg/kg BW
Table 2
Horse strongyles egg per gram (EPG) mean values, percentage of fecal egg count reduction (in brackets) and standard deviation (SD) in a population of horses from Sardinia Island, Italy investigated for the efﬁcacy of ﬁve com-
mercial formulations from Day 0 (D0) to Day 150 (D150).
Drug D0 D7 D14 D21 D28 D45 D60 D75 D90 D105 D120 D135 D150
IVM 1 Mean EPG 1906 0 (100%) 0 (100%) 1 (99.9%) 5.36 (99.7%) 0 (100%) 16.2 (99.3%) 158.7 (92.8%) 295.9 (87%) 279.4(85.3%) 403.1(79.4%) 582.9 (75.8%) 1112.5 (57.3%)
SD 1516.8 0 0 3.8 20.0 0 31.6 260.1 419.4 390.9 496.4 651.6 1246.7
IVM 2 Mean EPG 1504.4 6.2 (99.6%) 8.8 (99.4%) 6.2 (99.6%) 0 (100%) 0 (100%) 29.1 (98.1%) 157 (90.5%) 141.4 (91.1%) 64.5 (93.3%) 57.9 (91.3%) 38.6 (90.8%) 60 (87.7%)
SD 1531.4 25.5 36.4 25.4 0 0 90.2 371.4 248.6 106.3 45.3 72.4 38.2
MOX Mean EPG 997.5 0 (100%) 0 (100%) 0 (100%) 0 (100%) 0 (100%) 0 (100%) 0 (100%) 13.3 (98.8%) 42.9 (96.8%) 0 (97%) 18 (95.8%) 45 (94%)
SD 493.9 0 0 0 0 0 0 0 40 106.9 0 40.2 90
PYR Mean EPG 1405.3 15.8 (98.9%) 15.8 (98.9%) 30 (97.9%) 21.7 (96%) 46.8 (93.7%) 92.8 (93.7%) 135 (91.1%) 167.8 (88.7%) 236.8 (84.7%) 351.2 (78.1%) 242.1 (77.9%) 537.5 (70.5%)
SD 1043.8 19.7 53.4 38.2 23.7 58.3 142.7 127.3 189.7 195.1 391.7 196 440.6
FBZ Mean EPG 1113.5 5.4 (99.5%) 10.7 (99%) 12.8 (98.7%) 11.5 (99%) 32.3 (97.1%) 155.8 (86%) 197.3 (82.3%) 375 (69.2%) 456.4 (56.5%) 595 (44.7%) 1675 (14.5%) 1770 (0%)
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No signiﬁcant differences between treatment groups were found at D0 (P N 0.05), with mean EPG values ranging from
997.5 ± 493.92 to 1906 ± 1516.8 (Table 2). The FECR values at D14 in each treatment group constantly showed a ≥95% reduction
with the 95% C.I. N90%. In particular in IVM1 group the efﬁcacy was 100% on D14 and until D75 in the MOX group (Table 2). FBZ
group exceeded the ERP parameter at D60 (86% efﬁcacy), the groups treated with PYR and IVM1 at D90 (88.7% and 87% respectively),
group treatedwith IVM2 at D150 (87.7%) while groupMOX for all the duration of the trial presented FECR efﬁcacy N90% (94% at D150)
(Table 2). Larvae harvested at coprocultures carried out on samples collected at D0 were identiﬁed as Cyathostominae (96.4%),
Oesophagodontus spp. (1.5%), Strongylus vulgaris (1.3%), Gyalocephalus capitatus (0.4%), Trichostrongylus axei (0.3%), Strongylus equinus
(0.1%), Triodontophorus spp. (0.01%), and Strongylus edentatus (0.01%). All larvae recovered from coprocultures performed on post-
treatment samples with values ≥150 EPG were identiﬁed as cyathostomins. No side effects were recorded throughout the study in
the treated animals.
4. Discussion
The present study provides information on the efﬁcacy of the most commonly used anthelmintics against IS in a horse popu-
lation in Sardinia. All drugs evaluated in the trial were effective on D14 and no evidence of shortened strongyle ERP was found. As
expected, Cyathostominae were predominant (96.4%) in the examined horses, as already reported elsewhere (Peregrine et al.,
2014; Molento et al., 2012; Geurden et al., 2014; Larsen et al., 2011). Nonetheless, this study showed no evidence of AR in the
examined animals. In Italy, resistance to BZ of small strongyles has been reported for the ﬁrst time in Northern breedings
(Genchi et al., 1992), while AR to BZ and to PYR has been mostly found in central and northern regions (Traversa et al., 2007),
and later, other than a wide distribution of resistance to BZ and PYR, a reduced efﬁcacy of IVM was also described in regions
of continental Italy (Traversa et al., 2009). A recent survey carried out in ten different Italian locations has shown efﬁcacy of
IVM below the 90% ERP threshold on 3 farms on Day 56, and efﬁcacy of MOX below 90% only on 1 study site on Day 84 and
from Day 42 onwards in another farm (Geurden et al., 2014).
The present results, although the number of investigated horses was not high, differ from those achieved in continental Italy
and other European countries, where drug resistant cyathostomins are spread and the ERP is reduced for FBZ, PYR and, though
with a lesser to extent, for IVM and MOX as well. The absence of drug resistance in the examined population of Sardinian horses
could be related, besides its insularity (i.e. natural boundaries prevent from the introduction of resistant parasite populations), to
the frequency of anthelmintic treatments in the Island. In fact, more than half of the population of Sardinian horses receives a
parasiticide less than 2 times per year (Montinaro et al., 2002), thus pressure for selection of resistance is minimal if compared
to other management practice. Also, climatic variables could play an important role. In fact, the mild temperate weather of the
island allows a high survival rate of environmental L3 all year round, thus preserving the amount of those parasitic stages
which do not become in contact with parasiticides and are not selected for resistance, i.e. refugia (Nielsen et al., 2014). Although
in Italy anthelmintics are sold as veterinary prescription-only medications, a parasitological diagnosis prior to treatment is not
required as, for instance, in Denmark where this approach is considered a potential strategy to limit AR in horses (Sallé and
Cabaret, 2015).
Similar control plans would be desirable in other settings, in fact a recent questionnaire survey on intestinal worm control
practices in horses in Italy showed that only 9.3% of respondents usually dewormed animals after a fecal examination and
61.3% dewormed all horses together (Papini et al., 2015). In fact, as an appropriate use of anthelmintics, along with high-
standard practice management, is essential to limit or prevent the development and spread of AR, a prescription-based only treat-
ment would be powerful to reduce the spread of resistant cyathostomins where they are already present and to prevent their
introduction in the free regions.
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